201 related articles for article (PubMed ID: 14751930)
1. A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion.
Lee KN; Jackson KW; Christiansen VJ; Chung KH; McKee PA
Blood; 2004 May; 103(10):3783-8. PubMed ID: 14751930
[TBL] [Abstract][Full Text] [Related]
2. Alpha2-antiplasmin: potential therapeutic roles in fibrin survival and removal.
Lee KN; Jackson KW; Christiansen VJ; Chung KH; McKee PA
Curr Med Chem Cardiovasc Hematol Agents; 2004 Oct; 2(4):303-10. PubMed ID: 15320781
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-antiplasmin.
Lee KN; Jackson KW; Christiansen VJ; Dolence EK; McKee PA
J Thromb Haemost; 2011 May; 9(5):987-96. PubMed ID: 21251197
[TBL] [Abstract][Full Text] [Related]
4. Why alpha-antiplasmin must be converted to a derivative form for optimal function.
Lee KN; Jackson KW; Christiansen VJ; Lee CS; Chun JG; McKee PA
J Thromb Haemost; 2007 Oct; 5(10):2095-104. PubMed ID: 17883704
[TBL] [Abstract][Full Text] [Related]
5. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein.
Lee KN; Jackson KW; Christiansen VJ; Lee CS; Chun JG; McKee PA
Blood; 2006 Feb; 107(4):1397-404. PubMed ID: 16223769
[TBL] [Abstract][Full Text] [Related]
6. The level of circulating fibroblast activation protein correlates with incorporation of alpha-2-antiplasmin into the fibrin clot.
Uitte de Willige S; Malfliet JJCM; Abdul S; Leebeek FWG; Rijken DC
Thromb Res; 2018 Jun; 166():19-21. PubMed ID: 29649768
[TBL] [Abstract][Full Text] [Related]
7. Addition of a sequence from alpha2-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis.
Sheffield WP; Eltringham-Smith LJ; Gataiance S; Bhakta V
BMC Biotechnol; 2009 Mar; 9():15. PubMed ID: 19257897
[TBL] [Abstract][Full Text] [Related]
8. Natural heterogeneity of α2-antiplasmin: functional and clinical consequences.
Abdul S; Leebeek FW; Rijken DC; Uitte de Willige S
Blood; 2016 Feb; 127(5):538-45. PubMed ID: 26626994
[TBL] [Abstract][Full Text] [Related]
9. Characterization of wild-type and mutant alpha2-antiplasmins: fibrinolysis enhancement by reactive site mutant.
Lee KN; Tae WC; Jackson KW; Kwon SH; McKee PA
Blood; 1999 Jul; 94(1):164-71. PubMed ID: 10381509
[TBL] [Abstract][Full Text] [Related]
10. Increased N-terminal cleavage of alpha-2-antiplasmin in patients with liver cirrhosis.
Uitte de Willige S; Malfliet JJ; Janssen HL; Leebeek FW; Rijken DC
J Thromb Haemost; 2013 Nov; 11(11):2029-36. PubMed ID: 24034420
[TBL] [Abstract][Full Text] [Related]
11. Effect of phenylglyoxal-modified alpha2-antiplasmin on urokinase-induced fibrinolysis.
Lee KN; Lee SC; Jackson KW; Tae WC; Schwartzott DG; McKee PA
Thromb Haemost; 1998 Oct; 80(4):637-44. PubMed ID: 9798984
[TBL] [Abstract][Full Text] [Related]
12. Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation.
Mosesson MW; Siebenlist KR; Hernandez I; Lee KN; Christiansen VJ; McKee PA
J Thromb Haemost; 2008 Sep; 6(9):1565-70. PubMed ID: 18564219
[TBL] [Abstract][Full Text] [Related]
13. Generation and characterization of monoclonal antibodies against the N-terminus of alpha-2-antiplasmin.
Abdul S; Peeters M; Brouwers E; Malfliet JJMC; Leebeek FWG; Declerck PJ; Rijken DC; Uitte de Willige S
PLoS One; 2018; 13(5):e0196911. PubMed ID: 29723259
[TBL] [Abstract][Full Text] [Related]
14. Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design.
Lee KN; Jackson KW; Terzyan S; Christiansen VJ; McKee PA
Biochemistry; 2009 Jun; 48(23):5149-58. PubMed ID: 19402713
[TBL] [Abstract][Full Text] [Related]
15. The effect of a single nucleotide polymorphism on human alpha 2-antiplasmin activity.
Christiansen VJ; Jackson KW; Lee KN; McKee PA
Blood; 2007 Jun; 109(12):5286-92. PubMed ID: 17317851
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Fibrinolysis by Coagulation Factor XIII.
Rijken DC; Uitte de Willige S
Biomed Res Int; 2017; 2017():1209676. PubMed ID: 28761875
[TBL] [Abstract][Full Text] [Related]
17. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis.
Schneider M; Nesheim M
J Biol Chem; 2004 Apr; 279(14):13333-9. PubMed ID: 14715655
[TBL] [Abstract][Full Text] [Related]
18. A novel method to quantify fibrin-fibrin and fibrin-α
Morrow GB; Flannery S; Charles PD; Heilig R; Feller T; McQuilten Z; Wake E; Ariens RAS; Winearls J; Mutch NJ; Fischer R; Laffan MA; Curry N
J Thromb Haemost; 2024 Jun; 22(6):1758-1771. PubMed ID: 38462220
[TBL] [Abstract][Full Text] [Related]
19. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor.
Sakata Y; Aoki N
J Clin Invest; 1980 Feb; 65(2):290-7. PubMed ID: 6444305
[TBL] [Abstract][Full Text] [Related]
20. The role of alpha 2-antiplasmin in the inhibition of clot lysis in newborns and adults.
Ries M; Klinge J; Rauch R; Keuper H; Harms D
Biol Neonate; 1996; 69(5):298-306. PubMed ID: 8790908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
